Long-term safety and effectiveness of ritonavir (RTV), nelfinavir (NFV) and lopinavir/ritonavir (LPWr) in antiretroviral (ARV)-experienced HIV-1-infected children

被引：0
|
作者：
Rudin, Christoph
Burri, Marcus
Shen, Yang
Rode, Richard
Nadal, David
机构：
[1] Univ Basel, Childrens Hosp, Basel, Switzerland
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Univ Zurich, Childrens Hosp, Div Infect Dis, Zurich, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2007年 / 137卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [41] PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged ≥3 months to <6 years
    Strehlau, Renate
    Pena Donati, Anamaria
    Martinez Arce, Pedro
    Lissens, Jurgen
    Yang, Rong
    Biguenet, Sophie
    Cambilargiu, Daniela
    Hardy, Helene
    Correll, Todd
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [42] Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial
    Orkin, C.
    DeJesus, E.
    Khanlou, H.
    Stoehr, A.
    Supparatpinyo, K.
    Lathouwers, E.
    Lefebvre, E.
    Opsomer, M.
    Van de Casteele, T.
    Tomaka, F.
    HIV MEDICINE, 2013, 14 (01) : 49 - 59
  • [43] COST EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV plus RTV) REGIMENS FOR ANTIRETROVIRAL (ARV) NAIVE HIV-I INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY: APPLICATION TO GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
    Simpson, K. N.
    Dietz, B.
    Baran, R. W.
    Kirbach, S. E.
    Podsadecki, T.
    VALUE IN HEALTH, 2010, 13 (03) : A193 - A193
  • [44] No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir
    Baroncelli, Silvia
    Mezzaroma, Ivano
    Fantauzzi, Alessandra
    Galluzzo, Clementina M.
    Antoni, Anna Degli
    Vullo, Vincenzo
    Francisci, Daniela
    Ladisa, Nicoletta
    Vivarelli, Angela
    Cirioni, Oscar
    Sighinolfi, Laura
    Weimer, Liliana E.
    Fragola, Vincenzo
    Fidanza, Rina
    Cara, Andrea
    Palmisano, Lucia
    ANTIVIRAL THERAPY, 2013, 18 (03) : 321 - 327
  • [45] Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
    Delaugerre, C.
    Buyck, J. F.
    Peytavin, G.
    Viard, J. P.
    Chaix, M. L.
    Zucman, D.
    Mortier, E.
    Blanche, S.
    Rouveix, E.
    Force, G.
    Aegerter, P.
    De Truchis, P.
    JOURNAL OF CLINICAL VIROLOGY, 2010, 47 (03) : 248 - 252
  • [46] Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
    Antinori, Andrea
    Galli, Massimo
    Gianotti, Nicola
    Mussini, Cristina
    Quirino, Tiziana
    Sterrantino, Katia
    Mancusi, Daniela
    Termini, Roberta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 179 - 180
  • [47] LONG-TERM SAFETY OF A DUAL REGIMEN OF RALTEGRAVIR AND RITONAVIR-BOOSTED PROTEASE INHIBITOR IN ARV-EXPERIENCED PATIENTS WITH CHRONIC KIDNEY DISEASE
    Segala, D.
    Roda, R.
    Libanore, M.
    Sighinolfi, L.
    INFECTION, 2011, 39 : S76 - S76
  • [48] Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy
    Kempf, DJ
    Isaacson, JD
    King, MS
    Brun, SC
    Sylte, J
    Richards, B
    Bernstein, B
    Rode, R
    Sun, E
    ANTIVIRAL THERAPY, 2002, 7 (03) : 165 - 174
  • [49] Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy
    Zanchetta, Marisa
    Walker, Sarah
    Burighel, Nicoletta
    Bellanova, Domenico
    Rampon, Osvalda
    Giaquinto, Carlo
    De Rossi, Anita
    JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (12): : 1718 - 1727
  • [50] Treatment of advanced HIV disease in antiretroviral-naive HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine
    Uy, Jonathan
    Yang, Rong
    Wirtz, Victoria
    Sheppard, Louise
    Farajallah, Awny
    McGrath, Donnie
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2011, 23 (11): : 1500 - 1504
12345